文献速递其他结缔组织病

系统性硬化症外周B淋巴细胞分泌IL-6和TGFβ并激活成纤维细胞

Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts.
PubMed 文献 · Arthritis Rheumatol · 2017-01-01

该研究分析系统性硬化症(SSc)患者外周B细胞亚群及IL-6/TGFβ分泌,发现SSc患者活化B细胞比例增加,dcSSc患者B细胞CD5、CD86、IL-6R、IL-21R阳性比例更高,且SSc患者B细胞分泌IL-6和TGFβ增多,其上清可促进成纤维细胞增殖和胶原产生。

要点

  • SSc患者外周活化B细胞(CD69+、CD95+)比例增加。
  • dcSSc患者B细胞CD5、CD86、IL-6R、IL-21R阳性比例高于lcSSc和健康对照。
  • SSc患者B细胞分泌IL-6和TGFβ增多,上清促进成纤维细胞增殖和胶原产生。

核心结论

  • SSc患者外周活化B细胞数量增加,CD5、CD86、IL-6R和IL-21R上调可区分dcSSc与lcSSc。
  • SSc患者外周B淋巴细胞分泌IL-6和TGFβ,并在体外激活成纤维细胞。

研究设计与样本

  • 采用流式细胞术和多因子检测分析外周B细胞亚群及IL-6、TGFβ产生。
  • 采用XTT、溴脱氧尿苷和Ki-67评估与SSc患者或健康对照B细胞上清共孵育后的成纤维细胞增殖率,并用胶原检测评估胶原产生。

主要发现

  • SSc患者中表达CD69和CD95的B细胞比例增加。
  • dcSSc患者B细胞CD5阳性比例(均值±标准差24.12±7.93%)高于lcSSc(14.09±6.58%,P=0.03)和健康对照(14.21±5.34%,P=0.01)。
  • dcSSc患者B细胞CD86阳性比例(39.89±22.11%)高于lcSSc(17.72±13.98%,P=0.0007)和健康对照(11.68±11.09%,P<0.001)。
  • dcSSc患者B细胞IL-6R阳性比例(33.64±23.12%)高于lcSSc(17.91±13.62%,P<0.0001)和健康对照(12.08±8.68%,P=0.0009)。
  • dcSSc患者B细胞IL-21R阳性比例(32.55±20.19%)高于lcSSc(5.76±4.40%,P<0.0001)和健康对照(5.93±3.29%,P<0.0001)。

临床怎么用

  • SSc患者外周B细胞呈活化表型,B细胞来源IL-6和TGFβ可能参与成纤维细胞激活。
  • CD5、CD86、IL-6R和IL-21R在B细胞上的表达差异有助于区分dcSSc与lcSSc。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the role of B lymphocytes in systemic sclerosis (SSc). METHODS: Peripheral B cell subpopulations and the production of interleukin-6 (IL-6) and transforming growth factor β (TGFβ) were analyzed using flow cytometry and multiplex assay. The fibroblast proliferation rate upon incubation with supernatants from B cells isolated from SSc patients or healthy controls was assessed using XTT, bromodeoxyuridine, and Ki-67. Collagen production was assessed using a collagen assay. RESULTS: Ninety untreated patients (12 males) fulfilling the American College of Rheumatology/European League Against Rheumatism criteria for SSc (23 with diffuse cutaneous SSc [dcSSc] and 67 with limited cutaneous SSc [lcSSc]) and 30 healthy controls were recruited. Increased proportions of B cells expressing CD69 and CD95 were identified among the patients with SSc. B lymphocytes from dcSSc patients versus lcSSc patients and healthy controls expressed increased proportion of cells positive for CD5 (mean ± SD 24.12 ± 7.93% versus 14.09 ± 6.58% [P = 0.03] and 14.21 ± 5.34% [P = 0.01]), CD86 (39.89 ± 22.11% versus 17.72 ± 13.98% [P = 0.0007] and 11.68 ± 11.09% [P < 0.001]), IL-6 receptor (IL-6R; 33.64 ± 23.12% versus 17.91 ± 13.62% [P < 0.0001] and 12.08 ± 8.68% [P = 0.0009]), or IL-21R (32.55 ± 20.19% versus 5.76 ± 4.40% [P < 0.0001] and 5.93 ± 3.29% [P < 0.0001]). In addition, the levels of IL-6 (mean ± SD 314.3 ± 317.8 pg/ml versus 6.10 ± 2.58 pg/ml; P = 0.0007) and TGFβ (mean ± SD 1,020 ± 569 pg/ml versus 163.8 ± 98.69 pg/ml; P = 0.001) secreted by B lymphocytes from patients with SSc were increased compared to healthy controls. Fibroblast proliferation and collagen production were also significantly increased in the presence of B cell supernatant from SSc patients as compared to healthy controls. CONCLUSION: The numbers of activated B cells were increased in SSc patients, and the up-regulation of CD5, CD86, IL-6R, and IL-21R discriminated between patients with dcSSc and those with lcSSc. Peripheral B lymphocytes from SSc patients secreted both IL-6 and TGFβ, and they activated fibroblasts in vitro.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Dumoitier N, Chaigne B, Régent A, et al. Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts. Arthritis Rheumatol. 2017. PMID: 27992693. doi:10.1002/art.40016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。